Axinn Protects Client Endo Pharmaceuticals Inc.’s Approval for Generic Valcyte®
March 11, 2015
Axinn, on behalf of client Endo Pharmaceuticals Inc., successfully defended the U.S. Food and Drug Administration’s final approval of Endo’s generic Valcyte® by securing summary judgment in favor of Endo and FDA. Plaintiff Ranbaxy Laboratories, Ltd. had sought an order reversing FDA’s approval of Endo’s generic Valcyte® product after FDA recently decided to revoke tentative approval of Ranbaxy’s generic Valcyte® ANDA and determined that Ranbaxy had forfeited its generic marketing exclusivity rights. Judge Beryl Howell of the United Stated District Court for the District of Columbia determined that FDA had acted within its authority.
Related People
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Kenina Lee Selected as a Member of Law360’s 2026 Competition Editorial Advisory Board
Awards & Recognitions
Antitrust
Axinn Associates at the Antitrust Spring Meeting: You Get a Deal, You Get a Deal—A Deal in Every Environment
Axinn Viewpoints
Antitrust
Axinn Associates at the Spring Meeting: Trends in Federal Antitrust Enforcement and Policy
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Cartel Enforcement Trends and Developments
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Tech-Related Enforcement
Axinn Viewpoints
Antitrust
Leadership Across the Generations: A Conversation Between Mentor and Mentee
Byline Articles
Antitrust
Ultramarathons Make Me A Better Lawyer
Byline Articles
Antitrust
